Individualized Obesity Pharmacotherapy

NCT03374956 PHASE3 COMPLETED Results posted

The researchers are trying to identify the specific characteristics (phenotypes) that may be useful to help select the right medication for weight loss.

Details

Lead sponsor	Mayo Clinic
Phase	PHASE3
Status	COMPLETED
Enrolment	193
Start date	Mon Dec 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu May 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Obesity

Interventions

• Phentermine-Topiramate
• Liraglutide
• Naltrexone/bupropion
• Phentermine

Countries

United States